Journal of Medicine and Life Science

Institute for Medical Science (제주대학교 의과학연구소)
권호 표지
DOI QR코드

DOI QR Code

Complementary health education and clinical guidance for treating women experiencing infertility along with unexplained resistant hyperprolactinemia

  • Atef M.M. Darwish (Department of Obstetrics & Gynecology, Assiut University Faculty of Medicine) ;
  • Dina A.M. Darwish (Department of Obstetrics & Gynecology, Assiut University Faculty of Medicine)
  • Received : 2023.07.18
  • Accepted : 2023.11.05
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

This study prospective randomized controlled trial aims to test the impact of adding health education, awareness of some contributing factors and clinical guidance to therapeutic cabergoline given to infertile women with unexplained resistant hyperprolactinemia. It comprised 120 infertile women with unexplained persistent hyperprolactinemia not responding to therapeutic doses of cabergoline 1.5-2 mg/week who were subjected to proper history taking to exclude concomitant drug intake or possible brain problems in all cases. They were classified into group A (60 cases) who received health education and clinical guidance to search for possible contributing factors and were instructed to avoid them in addition to proper therapeutic doses of cabergoline, while group B (60 cases) received proper therapeutic doses of cabergoline only without clinical guidance. After 1 month, serum prolactin (PRL) was measured for all cases. All cases had high PRL level at the start of the study (79.9±28.4 [39-195] and 78.2±19.9 [42-189] in group A and B, respectively) without any significant difference. Pretreatment counselling revealed that lifestyle factors, sexual behaviors or feeding habits may contribute to resistant hyperprolactinemia in all cases without a significant difference between both groups. Serum PRL dropped significantly more in group A (20.14±10.31 [11-45] vs. 49.32±37.03 [12-100]) after combined health education, clinical guidance of the couple and proper treatment. It is concluded that lifestyle factors, sexual behaviors, and feeding habits would affect the response of hyperprolactinemia to treatment. Health education and clinical guidance with some advice to avoid them, would concomitantly improve the response of resistant hyperprolactinemia to therapeutic doses of dopamine agonists.

Keywords

References

  1. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273-88. https://doi.org/10.1210/jc.2010-1692
  2. Rubio-Abadal E, Del Cacho N, Saenz-Navarrete G, Arranz B, Cambra RM, Cuadras D, et al. How hyperprolactinemia affects sexual function in patients under antipsychotic treatment. J Clin Psychopharmacol 2016;36:422-8. https://doi.org/10.1097/JCP.0000000000000539
  3. Lee DY, Oh YK, Yoon BK, Choi D. Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems. Am J Obstet Gynecol 2012;206:213.e1-5. https://doi.org/10.1016/j.ajog.2011.12.010
  4. Oh MC, Kunwar S, Blevins L, Aghi MK. Medical versus surgical management of prolactinomas. Neurosurg Clin N Am 2012;23:669-78. https://doi.org/10.1016/j.nec.2012.06.010
  5. Dai C, Sun B, Guan S, Wang W, Liu H, Li Y, et al. Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review. BMC Endocr Disord 2021;21:217.
  6. Maiter D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 2019;109:42-50. https://doi.org/10.1159/000495775
  7. Davies PH. Drug-related hyperprolactinaemia. Adverse Drug React Toxicol Rev 1997;16:83-94.
  8. Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci 2013;6:168-75. https://doi.org/10.4103/0974-1208.121400
  9. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008;93:4721-7. https://doi.org/10.1210/jc.2007-2758
  10. Venkatanarasu A, Boddula R, Basavaraju S, Chinte C, Tickoo V. Drug induced hyperprolactinemia. J Endocr Soc 2021;5(Suppl 1):A626-7. https://doi.org/10.1210/jendso/bvab048.1277
  11. Connelly LM. Cronbach's alpha. Medsurg Nurs 2011;20:44-5.
  12. Darwish A, Abdellah MS, AbdelAleem MA. Hyperprolactinemia and woman's health. In: Darwish A editor. Basic gynecology: some related issues. London: InTech; 2012. pp.1-47.
  13. Speroff L. Amenorrhea. In: Speroff L, Glass RH, Kase NG, editors. Clinical gynecologic endocrinology and infertility. 4th ed. Baltimore: Williams and Wilkins; 1989. pp.165-211.
  14. AbdElghani SE, Elmugadam A, Elsanousi M. Hyperprolactinemia as a cause of female primary infertility and its prevalence in Gezira State, Central Sudan. Egypt Acad J Biol 2013;5:31-6. https://doi.org/10.21608/eajbsc.2013.16107
  15. Rashid J, Hussain M, Ahmad J, Ahmad R, Rashid S, Iftikhar M, et al. Clinical profile and changing etiological spectrum of hyperprolactinemia at a tertiary care endocrine facility. Endocrinol Res Pract 2020;24:308-13. https://doi.org/10.25179/tjem.2020-77992
  16. Zargar AH, Laway BA, Masoodi SR, Bhat MH, Wani AI, Bashir MI, et al. Clinical and etiological profile of hyperprolactinemia--data from a tertiary care centre. J Assoc Physicians India 2005;53:288-90.
  17. Huang W, Molitch ME. Evaluation and management of galactorrhea. Am Fam Physician 2012;85:1073-80.
  18. Sakiyama R, Quan M. Galactorrhea and hyperprolactinemia. Obstet Gynecol Surv 1983;38:689-700. https://doi.org/10.1097/00006254-198312000-00001
  19. Dissanayake H, Keerthisena S, Dematapitiya C, Katulanda P. Emotionally induced galactorrhoea in a non-lactating female--"pseudo-lactation"? BMC Endocr Disord 2014;14:98.
  20. Verma D. Symptoms of hyperprolactinemia with normal serum prolactin: is treatment required? Int J Reprod Contracept Obstet Gynecol 2016;5:2041-2. https://doi.org/10.18203/2320-1770.ijrcog20161715
  21. Melmed S, Kleinberg D. Anterior pituitary. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, editors. Williams Textbook fo endocrinology. 10th ed. Amsterdam: Elsevier; 2003. pp.155-261.
  22. Bonhoff A, Vuille JC, Gomez F, Gellersen B. Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL-IgG complex. Exp Clin Endocrinol Diabetes 1995;103:252-5. https://doi.org/10.1055/s-0029-1211358
  23. Hattori N, Ishihara T, Saiki Y, Shimatsu A. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up. Clin Endocrinol (Oxf) 2010;73:792-7. https://doi.org/10.1111/j.1365-2265.2010.03880.x
  24. Soh NAAC, Yaacob NM, Omar J, Jelani AM, Shafii N, Ismail TST, et al. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis. Int J Environ Res Public Health 2020;17:8199.
  25. Leung AK, Pacaud D. Diagnosis and management of galactorrhea. Am Fam Physician 2004;70:543-50.
  26. Ali M, Mirza L. Morbid obesity due to prolactinoma and significant weight loss after dopamine agonist treatment. AACE Clin Case Rep 2021;7:204-6. https://doi.org/10.1016/j.aace.2021.01.004
  27. Pereira-Lima JF, Leaes CG, Neto FMF, Barbosa MV, da Silva ALM, da Costa Oliveira M. Hyperprolactinemia and body weight: prevalence of obesity and overweight in patients with hyperprolactinemia. Res J Endocrinol Metab 2013;1:2.
  28. dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011;19:800-5. https://doi.org/10.1038/oby.2010.150
  29. Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology 2011;152:526-35. https://doi.org/10.1210/en.2010-0668
  30. Yamaguchi M, Erdenebaatar C, Saito F, Honda R, Ohba T, Kyo S, et al. Prolactin enhances the proliferation of proliferative endometrial glandular cells and endometrial cancer cells. J Endocr Soc 2019;4:bvz029.
  31. Crosignani PG. Management of hyperprolactinemic infertility. Middle East Fertil Soc J 2012;17:63-9. https://doi.org/10.1016/j.mefs.2012.04.003
  32. Auriemma RS, Del Vecchio G, Scairati R, Pirchio R, Liccardi A, Verde N, et al. The interplay between prolactin and reproductive system: focus on uterine pathophysiology. Front Endocrinol (Lausanne) 2020;11:594370.
  33. Vreeland B, Kim E. Managing the clinical consequences of psychiatric illness and antipsychotic treatment: a discussion of obesity, diabetes, and hyperprolactinemia. J Am Psychiatr Nurses Assoc 2004;10 suppl 3:S17-24. https://doi.org/10.1177/1078390304265287
  34. de Greef WJ, Plotsky PM, Neill JD. Dopamine levels in hypophysial stalk plasma and prolactin levels in peripheral plasma of the lactating rat: effects of a simulated suckling stimulus. Neuroendocrinology 1981;32:229-33.  https://doi.org/10.1159/000123164